Out of the many different technological advances Elon Musk has done for humanity, the most controversial has to be Neuralink. We are talking about a company that is essentially creating micro chips that will eventually be implanted in human brains with a potential to make highly consequential innovations in neuro medicine. One of the most ambitious goals Neuralink has is to someday fight degenerative diseases such as Alzheimer’s, dementia, or other major illnesses. Until today, the possible existence of Neuralink chips was only in the developing stage but a recent announcement from Musk himself has proven that the tech mogul isn’t wating any time to move forward with this.
Neuralink is approved by the FDA
The Food and Drug Administration (FDA) ir the institution that always needs to peer review any type of technological advancement that can benefit the human way of life in the United States of America. They are the ones who approved vaccines, new medication, and other advances in science. Elon Musk just confirmed through a tweet that the FDA has officially approved Neuralink chip trials in humans. A major development for science that Musk announced by writing this:”We are excited to share that we have received the FDA’s approval to launch our first-in-human clinical study! An important first step that one day will allow our technology to help many people.”
It’s hard to not go down the rabbit hole and think about many ways in which this new technology could go terribly wrong. Musk has been pushing this for decades and he is 100% convinced this will be another one of his ideas that will keep saving humanity. But in reality, we won’t know for sure the impact Neuralink will have in the human brain until we get to see results from these trials. The FDA soon confirmed Musk’s news through a statement from a spokesperson: “The FDA acknowledges and understands that Neuralink has announced that its investigational device exemption … for its implant/R1 robot was approved by the FDA and that it may now begin conducting human clinical trials for its device.”
